![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Bioventus Launches Osteoarthritis Treatment in Taiwan
Bioventus Launches Osteoarthritis Treatment in Taiwan
January 5, 2016
Bioventus has launched in Taiwan its single-injection joint fluid Durolane for the treatment of osteoarthritis.
Durolane is indicated for the treatment of mild to moderate osteoarthritis of the knee.
The drug-device combo is based on a technology process called Nasha, which yields stabilized hyaluronic acid, a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. — Michael Cipriano
Upcoming Events
-
21Oct